ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences
(NASDAQ:IMA), SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) — ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” “Company”), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases, including IMG-007, an anti-OX40 monoclonal antibody with multiple differentiating features, today announced management participation in fourth quarter investor conferences. 2025 Stifel Healthcare ConferenceFireside Chat: Thursday, November […]